BioSpace News Archive

Biogen and Eisai announced positive topline results from their Phase II clinical trial of BAN2401 in Alzheimer’s disease.

Gilead may be down, but at least one analyst thinks the company is poised for a turnaround.

Has the U.S. Food and Drug Administration failed to do its due diligence in finding and reporting financial conflicts of interest between members of its scientific advisory committees and pharmaceutical companies?

Teva Pharmaceuticals is moving its U.S. headquarters to Parsippany-Troy Hills, New Jersey as part of a plan to centralize its operations in North America.

Negotiating for a salary increase does not have to be a painful process. While many people dread asking their boss for higher pay, if you prepare your case ahead of time and go into negotiations with clear evidence of your stellar performance, you’ll greatly increase your chances of getting the offer you want.

The Phadia 200 is CE-marked, and the first installations are underway at select European sites.

Cchek™ technology has demonstrated the ability to identify twenty different cancer types through a simple blood test.

Grant intended to evaluate the utility of MVT-2163 to improve pre-operative staging of patients with pancreatic cancer

Dr. Matkovits is Chief Operating Officer of ContraVir Pharmaceuticals

Details for the call and webcast, which will be available to the public and the media in listen-only mode